Results 31 to 40 of about 82,899 (261)

VIP treatment prevents embryo resorption by modulating efferocytosis and activation profile of maternal macrophages in the CBAxDBA resorption prone model [PDF]

open access: yes, 2016
Successful embryo implantation occurs followed by a local pro-inflammatory response subsequently shifted toward a tolerogenic one. VIP (vasoactive intestinal peptide) has embryotrofic, anti-inflammatory and tolerogenic effects.
Calo, Guillermina   +7 more
core   +1 more source

Vasoactive intestinal peptide: cardiovascular effects [PDF]

open access: yesCardiovascular Research, 2001
Vasoactive intestinal peptide (VIP) is present in the peripheral and the central nervous systems where it functions as a nonadrenergic, noncholinergic neurotransmitter or neuromodulator. Significant concentrations of VIP are present in the gastrointestinal tract, heart, lungs, thyroid, kidney, urinary bladder, genital organs and the brain.
R J, Henning, D R, Sawmiller
openaire   +2 more sources

An investigation into the relationship between small intestinal fluid secretion and systemic arterial blood pressure in the anesthetized rat [PDF]

open access: yes, 2015
In the absence of an ability to absorb fluid by cellular uptake mechanisms, fluid movement in vivo from the perfused rat intestine is absorptive when the diastolic blood pressure is normal or very low but is secretory when blood pressure falls below ...
Lucas, Michael, Morrison, James
core   +1 more source

Screening of a specific peptide binding to VPAC1 receptor from a phage display peptide library. [PDF]

open access: yesPLoS ONE, 2013
BACKGROUND/PURPOSE: The VPAC1 receptor, a member of the vasoactive intestinal peptide receptors (VIPRs), is overexpressed in the most frequently occurring malignant tumors and plays a major role in the progression and angiogenesis of a number of ...
Bo Tang   +4 more
doaj   +1 more source

Pheochromocytoma Producing Vasoactive Intestinal Peptide [PDF]

open access: yesMayo Clinic Proceedings, 2002
The syndrome of watery diarrhea associated with hypokalemia and achlorhydria was originally described in 1958. Subsequently, this syndrome was shown to be caused by a neuroendocrine tumor secreting vasoactive intestinal peptide (VIP), and such tumors are almost always pancreatic in origin.
Stephen L, Smith   +3 more
openaire   +2 more sources

Evaluation of a PACAP Peptide Analogue Labeled with (68)Ga Using Two Different Chelating Agents. [PDF]

open access: yes, 2016
OBJECTIVE: The authors have conjugated chelating agents (DOTA and NODAGA) with a peptide (pituitary adenylate cyclase-activating peptide [PACAP] analogue) that has a high affinity for VPAC1 receptors expressed on cancer cells.
Chen, Chang-Po   +6 more
core   +2 more sources

Longitudinal functional imaging of VIP interneurons reveals sup-population specific effects of stroke that are rescued with chemogenetic therapy

open access: yesNature Communications, 2021
Stroke profoundly disrupts cortical excitability which impedes recovery, but how stroke affects inhibitory interneurons is poorly understood. Here, the authors show that functional impairments after stroke are associated with the disruption of a highly ...
Mohamad Motaharinia   +6 more
doaj   +1 more source

Enhanced Mortality to Metastatic Bladder Cancer Cell Line MB49 in Vasoactive Intestinal Peptide Gene Knockout Mice

open access: yesFrontiers in Endocrinology, 2017
To identify if the absence of the vasoactive intestinal peptide (VIP) gene enhances susceptibility to death from metastatic bladder cancer, two strains of mice were injected with MB49 murine bladder cancer cells.
Niely Mirsaidi   +33 more
doaj   +1 more source

Augmented Cystine–Glutamate Exchange by Pituitary Adenylate Cyclase-activating Polypeptide Signaling via the VPAC1 Receptor [PDF]

open access: yes, 2014
In the central nervous system, cystine import in exchange for glutamate through system xc- is critical for the production of the antioxidant glutathione by astrocytes, as well as the maintenance of extracellular glutamate. Therefore, regulation of system
Arimura   +74 more
core   +2 more sources

Generation of KS-133 as a Novel Bicyclic Peptide with a Potent and Selective VIPR2 Antagonist Activity that Counteracts Cognitive Decline in a Mouse Model of Psychiatric Disorders

open access: yesFrontiers in Pharmacology, 2021
Worldwide, more than 20 million people suffer from schizophrenia, but effective and definitive new therapeutic drugs/treatments have not been established.
Kotaro Sakamoto   +16 more
doaj   +1 more source

Home - About - Disclaimer - Privacy